Quarterly report pursuant to Section 13 or 15(d)

Contingencies (Details)

Contingencies (Details) - action
4 Months Ended
Sep. 25, 2018
Aug. 28, 2018
In re Cancer Genetics, Inc. Securities Litigation    
Loss Contingencies [Line Items]    
Number of actions consolidated into one   2
Number of pending actions   1
Bell v. Sharma et al., McNeece v. Pappajohn et al., and Workman v. Pappajohn, et al.    
Loss Contingencies [Line Items]    
Cases filed against the Company and members of the Board of Directors 3